Ignite Creation Date:
2024-05-06 @ 7:12 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05934058
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-07-06
First Post:
2023-06-12
Brief Title:
Genomic and Dietary Aspects in Gastric Cancer Risk
Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organization:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study Overview
Official Title:
Interaction of Genomic and Dietary Aspects in Gastric Cancer Risk the Global StoP Project
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GenoStoP
Brief Summary:
Gastric Cancer GC ranks fourth in the number of deaths worldwide and it is sixth in Italy with almost 9000 deaths in 2020 Survival of GC is one of the lowest reported amongst major cancers thus making prevention a central priority for its control However there is currently a lack of evidence on gastric cancer determinants
Our study will pursue the following specific objectives
analyze dietary and lifestyle habits for GC also infrequent ones WP1
analyze major risk factors in rare patient subgroups WP2
develop a Genome-wide Modelling of polygenic risk score PRS in GC WP3
Our study will pursue the following specific objectives
analyze dietary and lifestyle habits for GC also infrequent ones WP1
analyze major risk factors in rare patient subgroups WP2
develop a Genome-wide Modelling of polygenic risk score PRS in GC WP3
Detailed Description:
The Stomach cancer Pooling project StoP Consortium dataset has grown to the current number of 35 studies from Europe America Middle East and Eastern Asia It will be used as the cornerstone upon which the investigation on the dietary and lifestyle determinants of gastric cancer GC will be built It will allow the analyses of relatively infrequent habits or exposures genetic factors as well as to perform sufficiently powered analyses of interactions and subgroups that may present relevant heterogeneity in the etiological correlates of GC
The potential of genomics to personalize and thereby improve diagnosis treatment and prognosis of individuals has long been recognized but so far evidence of the opportunity for genomics to drive prevention remains limited Recent advances in research on Polygenic Risk Score PRS have created new interest about the use of genetic information in prevention of common diseases and its application to risk stratification A long-lasting open question is whether common genetic variants used to build PRS are able to predict the risk of developing complex diseases with enough power to be used in a clinical setting
The lack of large enough dataset able to allow an unbiased PRS validation hampered this question to be answered for many years This study builds upon the StoP project a consortium collecting data from about 13500 GC cases and 32000 controls and the UK Biobank 480 GC cases and 338000 controls to develop a Polygenic Risk Score for gastric cancer
The potential of genomics to personalize and thereby improve diagnosis treatment and prognosis of individuals has long been recognized but so far evidence of the opportunity for genomics to drive prevention remains limited Recent advances in research on Polygenic Risk Score PRS have created new interest about the use of genetic information in prevention of common diseases and its application to risk stratification A long-lasting open question is whether common genetic variants used to build PRS are able to predict the risk of developing complex diseases with enough power to be used in a clinical setting
The lack of large enough dataset able to allow an unbiased PRS validation hampered this question to be answered for many years This study builds upon the StoP project a consortium collecting data from about 13500 GC cases and 32000 controls and the UK Biobank 480 GC cases and 338000 controls to develop a Polygenic Risk Score for gastric cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None